Thyroid effects in animals
Male rats fed very high dietary concentrations of erythrosine over their lifetimes developed thyroid follicular adenomas (benign tumours) at rates significantly above controls. Female rats fed the same amounts did not show a significant increase. Regulators and independent reviewers agree the mechanism is indirect: the sustained elevation of TSH caused by suppressed T3 production chronically overstimulates thyroid cells, and at extreme doses this drives tumour formation.
Male Sprague-Dawley rats fed 4% dietary erythrosine from gestation through a 30-month lifetime developed a high incidence of thyroid follicular adenomas. Female rats at the same dose did not show a significant increase.
1987AnimalBorzelleca et al., lifetime toxicity/carcinogenicity study in rats, cited in JECFA WHO Food Additives Series 28
Short-term rat studies found erythrosine decreases hepatic 5'-deiodinase activity, reducing conversion of T4 to T3 and raising TSH, consistent with the indirect hormonal mechanism for thyroid tumour development.
1990AnimalEffects of oral erythrosine on the pituitary-thyroid axis in rats, Toxicology and Applied Pharmacology, PubMed 2160137
EFSA concluded that the thyroid tumours in rats are secondary to the hormonal effects of erythrosine and are not due to any genotoxic activity. EFSA considered the rat findings of limited relevance to humans, given differences in thyroid physiology between rats and people.
2011Regulatory reviewEFSA Scientific Opinion on the re-evaluation of Erythrosine (E 127) as a food additive, EFSA Journal 2011:9(1):1854
Thyroid effects in humans
A controlled human study gave healthy men doses of 20, 60, or 200 mg of erythrosine daily for 14 days. At 200 mg per day, basal TSH rose and the TSH response to stimulation increased significantly. No effects were detected at 60 mg per day or below. EFSA and JECFA used the 60 mg per day no-effect level, with a tenfold safety factor, to set the ADI of 0.1 mg per kilogram of body weight per day.
In 30 healthy men, 200 mg erythrosine daily for 14 days raised basal serum TSH from 1.7 to 2.2 microU/ml and increased peak TSH response significantly. Doses of 20 and 60 mg daily produced no significant changes in thyroid hormone measures.
1987RCTEffects of oral erythrosine on thyroid function in normal men, Toxicology and Applied Pharmacology, PubMed 2447681
JECFA set an ADI of 0-0.1 mg per kg body weight per day, based on the human no-observed-effect level of 60 mg per person per day, applying a safety factor of 10. Human data were prioritised over the rat findings given species differences in thyroid physiology.
1991RegulatoryJECFA evaluation, WHO Food Additives Series 28, monograph 719
FDA ban under the Delaney Clause
In January 2025 the US FDA revoked authorisation for erythrosine in food and ingested drugs. The legal trigger was the Delaney Clause, a 1958 US law requiring the FDA to ban any additive shown to cause cancer in humans or animals, regardless of dose or mechanism. The FDA acknowledged it had no direct evidence of cancer in people and noted the animal mechanism may not apply to humans, but the Clause left no discretion once the animal tumour finding was established.
The FDA revoked authorisation for FD&C Red No. 3 (erythrosine) in food and ingested drugs on 15 January 2025, citing the Delaney Clause requirement following the established finding of thyroid tumours in male rats. Compliance dates are January 2027 for food and January 2028 for ingested drugs.
2025RegulatoryUS FDA, Federal Register, Revocation of Authorization for FD&C Red No. 3
Neurotoxicity signals in animal studies
Recent animal research found that erythrosine at doses including the ADI level, given daily for 28 days, produced measurable changes in rat brain tissue: suppressed antioxidant enzyme activity, increased lipid peroxidation, DNA strand damage in a comet assay, and abnormal brain cell appearance under microscopy. These are laboratory findings in rats, not human data, and the doses used are far above what typical consumption of the permitted foods would deliver.
Wistar rats given erythrosine at one quarter, one half, or the full ADI dose daily for 28 days showed suppressed antioxidant enzyme activity (CAT, SOD, GST), increased lipid peroxidation, reduced acetylcholinesterase activity, and DNA damage in the brain at all doses tested including the ADI level.
2025AnimalSingh and Chadha, Journal of Applied Toxicology, doi:10.1002/jat.4731
Genotoxicity and mutagenicity
Standard mutagenicity tests, reviewed repeatedly by JECFA and EFSA, found erythrosine to be non-genotoxic. Both bodies concluded the thyroid tumours in rats arose through an indirect hormonal mechanism rather than direct DNA damage. However, more recent in vitro and animal work using sensitive DNA-damage assays has found genotoxic signals at higher doses, creating some scientific disagreement that has not yet been resolved.
JECFA reviewed comprehensive mutagenicity data and concluded erythrosine is not genotoxic, with the rat thyroid tumours arising through hormonal overstimulation rather than direct mutagenic action.
1991Regulatory reviewJECFA, WHO Food Additives Series 28, monograph 719
An in vitro study using Allium cepa root meristematic cells found erythrosine induced cytotoxicity, mitotic abnormalities, and DNA damage signals, raising questions about genotoxic potential at higher concentrations.
2024LabAssessment of synthetic food dye erythrosine induced cytotoxicity, genotoxicity, biochemical and molecular alterations in Allium cepa root meristematic cells, PubMed 39132191